Sara Tylosky

About Sara Tylosky

When a company is entering Phase 2 or pivotal and hasn’t fully modeled what enrolling in certain markets could mean for post-trial access obligations, advocacy pressure, or regulatory alignment. It doesn’t happen in every program, but when it does, it creates avoidable tension between clinical ops, medical affairs, and leadership. I’ve seen companies enroll in certain regions and later realize they weren’t prepared for the access expectations that followed.I help rare and specialty biotechs align enrollment footprints with post-trial access and ethical exposure before pivotal decisions are locked — and ensure regulatory and access timelines reinforce capital discipline rather than conflict with it.

Experience

1. CEO

   Farmacon Global

   Oct 2015 — Present

   For >11 years our expert consultant network has specialized in Latin America & Latino populations to get enrollment results in complicated trials, including Rare Disease and other medical projects. Our unique concierge approach includes a database network of referring doctors, KOLs, & other venues to solve market research, enrollment strategies & logistical problems for sites, investigators, patients & their families, to gives sponsors the insurance they need to get the job done. We find, form & train teams, including site performance, developing KOLs, conducting surveys, & bringing the right feedback needed in a patient-centric world.

Education

• Florida Atlantic University

  Master of Business Administration (M.B.A.), Strategies

  1992 — 1994

• Whitman College

  Bachelor of Arts (B.A.), English, French minor

  1974 — 1978